Cancer BiologybioRxivPreprint
Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC
Luyao Ao, Wenjing Jia, Qixing Gong…·Jiali Liu
This study identifies GFPT2 as a metabolic checkpoint in EGFR-mutated NSCLC that promotes immune evasion, and shows that targeting GFPT2 enhances PD-1 blockade therapy.
3 citations